#glp-1-therapies

Novo Nordisk’s Ozempic India Price Cut Boosts Obesity Drug Sales

Novo Nordisk A/S saw a 40% surge in sales of its diabetes and weight-loss drugs in India last month, after steep price cuts boosted demand for its branded treatments even as generic GLP-1 therapies flood the market.